Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20
What Is The Anticipated Size Of The Non-Proliferative Diabetic Retinopathy Market Over The Five-Year Period 2025–2029?
The non-proliferative diabetic retinopathy market size has observed significant expansion in recent years. It is forecast to increase from $2.62 billion in 2024 to $2.83 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 8.1%. This historical growth can be attributed to an elevated prevalence of diabetes, an aging population, enhanced awareness, progress in research, evolving lifestyle habits, and improved management of diabetes.
The non-proliferative diabetic retinopathy market is projected to experience substantial expansion in the coming years. This market is anticipated to reach $3.77 billion by 2029, demonstrating a compound annual growth rate (CAGR) of 7.4%. Factors contributing to this growth during the forecast period include the uptake of telemedicine, the creation of innovative therapeutics, the incorporation of artificial intelligence, heightened investments in research and development, and the expansion of healthcare infrastructure. Key trends shaping this period encompass the growing integration of artificial intelligence for screening and diagnosis, a surge in demand for telemedicine and remote monitoring, the emergence of personalized medicine strategies for treating diabetic retinopathy, an increasing emphasis on preventive measures and early intervention, and the broadening significance of patient-centered care models in the management of diabetic retinopathy.
Unlock Your Free Sample Report for Exclusive Market Data:
https://www.thebusinessresearchcompany.com/sample.aspx?id=15620&type=smp
Which Factors And Drivers Are Influencing The Non-Proliferative Diabetic Retinopathy Market In 2025?
The escalating prevalence of diabetes is anticipated to propel the expansion of the non-proliferative diabetic retinopathy market going forward. Diabetes is a chronic metabolic disorder marked by elevated blood glucose, stemming from inadequate insulin production by the pancreas or the body’s cells developing resistance to insulin’s effects. This condition results from sedentary lifestyles, unhealthy dietary habits, and genetic predispositions. Diabetes induces non-proliferative diabetic retinopathy by damaging the blood vessels in the retina, primarily due to prolonged exposure to high levels of glucose in the bloodstream, which can lead to vision impairment and potential blindness. For instance, in June 2024, according to the National Health Service, a UK-based government department, in 2023, the NHS identified over half a million (549,000) additional individuals in England at risk of developing type 2 diabetes. This brought the total number of people with non-diabetic hyperglycemia, or pre-diabetes, registered with a GP, to 3,615,330. This represents a significant increase compared to 3,065,825 in 2022, highlighting a rise of nearly 20%. Consequently, the increasing prevalence of diabetes is driving the growth of the non-proliferative diabetic retinopathy market.
How Is The Non-Proliferative Diabetic Retinopathy Market Segmented?
The non-proliferative diabetic retinopathymarket covered in this report is segmented –
1) By Treatment Type: Anti-Vascular Endothelial Growth Factor (VEGF) Therapy; Intraocular Steroid Injection; Laser Surgery; Vitrectomy
2) By Disease Severity Level: Mild Non-Proliferative Diabetic Retinopathy; Moderate Non-Proliferative Diabetic Retinopathy; Severe Non-Proliferative Diabetic Retinopathy
3) By End-User: Hospitals; Specialty Clinics; Ambulatory Surgical Centers; Other End-Users
Subsegments:
1) By Anti-Vascular Endothelial Growth Factor (Vegf) Therapy: Bevacizumab (Avastin); Ranibizumab (Lucentis); Aflibercept (Eylea); Pegaptanib (Macugen)
2) By Intraocular Steroid Injection: Triamcinolone Acetonide; Dexamethasone Implant (Ozurdex); Fluocinolone Acetonide Implant (Iluvien)
3) By Laser Surgery: Focal Laser Photocoagulation; Panretinal Photocoagulation
4) By Vitrectomy: Pars Plana Vitrectomy (Ppv); Membrane Peeling Vitrectomy; Phaco-Vitrectomy (Combined Cataract And Vitrectomy Surgery)
What Are The Latest Industry Trends Transforming The Non-Proliferative Diabetic Retinopathy Market?
Leading enterprises within the non-proliferative diabetic retinopathy market are advancing AI-enabled cameras to enhance patient outcomes and progress the field of ophthalmic imaging. AI-equipped cameras in ophthalmic imaging denote devices fitted with artificial intelligence (AI) algorithms designed to aid in the capture, analysis, and interpretation of eye images for diagnostic and therapeutic purposes. For instance, in May 2024, Optomed, a Finland-based medical technology company, introduced Optomed Aurora AEYE, a handheld AI fundus camera developed for instant detection of more than mild diabetic retinopathy. This innovative apparatus blends the portability of a handheld camera with the power of artificial intelligence to supply high-quality retinal images for the early identification and monitoring of various eye conditions. The Optomed Aurora AEYE leverages AI algorithms to assist healthcare professionals in examining retinal images, thereby enabling quick and accurate diagnoses of conditions such as diabetic retinopathy, glaucoma, and age-related macular degeneration.
Which Key Market Players Are Investing In Expansion And Innovation Of Non-Proliferative Diabetic Retinopathy Market?
Major companies operating in the non-proliferative diabetic retinopathy market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche AG, AbbVie Inc., Bayer AG, Abbott Laboratories, Novartis AG, Eli Lilly and Company, Novo Nordisk A/S, Regeneron Pharmaceuticals Inc., Bausch Health Companies Inc., Boehringer Ingelheim International GmbH, Genentech Inc., Carl Zeiss Meditec AG, ZEISS Group, Santen Pharmaceutical Co. Ltd., Santen Inc., Topcon Corporation, Lumenis Ltd., Alimera Science, Ocular Therapeutix Inc., Acucela Inc., Ampio Pharmaceuticals, Kowa Company Ltd., Nidek Co. Ltd.
Download The Full Report For Exclusive Market Findings:
Which Region Currently Holds The Largest Share Of The Non-Proliferative Diabetic Retinopathy Market?
North America was the largest region in the non-proliferative diabetic retinopathy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the non-proliferative diabetic retinopathy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Version Of The Non-Proliferative Diabetic Retinopathy Market Report:
https://www.thebusinessresearchcompany.com/customise?id=15620&type=smp
Browse Through More Reports Similar to the Global Non-Proliferative Diabetic Retinopathy Market 2025, By The Business Research Company
Diabetic Foot Ulcer Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/diabetic-foot-ulcer-global-market-report
Proliferative Diabetic Retinopathy Pdr Global Market Report 2025
Diabetic Gastroparesis Treatment Global Market Report 2025
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model